Cecilia Hofvander, Director Investor Relations & Communications Phone: +46 46 540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com. This information was submitted for publication, through the agency of the contact persons set out above, at 08.30 a.m. CET on January 21, 2021. About Alligator Bioscience AB

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's

Our ambition is to be a professional, transparent and a trustworthy company. Cecilia Hofvander Director Investor Relations & Communications på Alligator Bioscience AB Bjärred, Skåne län, Sverige 382 kontakter Alligator Bioscience’s rights issue oversubscribed Wed, Jan 27, 2021 18:20 CET. Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareholders, which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the annual general meeting on May 5, 2020 (the Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com. Denna information är sådan information som Alligator Bioscience AB (publ) är skyldigt att offentliggöra enligt lagen om värdepappersmarknaden. The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the authorization from the Annual General Meeting on May 5, 2020, to carry out a new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 86 million (the “Rights Issue”). Board member of Clinical Laserthermia Systems AB and CB Ocean Capital AB. Deputy Board member of Endo Medical AB. Partner of Immunova HB. Holdings in Alligator: 1,200,833 shares. Non-independent in relation to the Company and its senior management, but independent in relation to major shareholders. Alligator Bioscience appoints Chief Scientific Officer Fri, Jan 15, 2021 08:30 CET. Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark as Chief Scientific Officer (CSO).

Organiskt minskade försäljningen med 6 procent. • Justerat 1) rörelseresultat ökade till 916 MSEK (915). Charlotte Parry, Head of Investor Relations. T: 0207 290 1072.

Alligator Bioscience AB (”Alligator” eller ”Bolaget”), ett ledande bioteknikföretag som utvecklar innovativa immunaktiverande antikroppsläkemedel för tumörriktad immunterapi, offentliggör härmed utfallet av erbjudandet att förvärva aktier i Bolaget (”Erbjudandet”) samt noteringen på Nasdaq Stockholm.

ALLGF: Alligator Bioscience AB. EXCHANGE OTCBB. SECTOR / SEGMENT / INDUSTRY Rein Piir, VP IR, rein.piir@alligatorbioscience.com, 046 286 42 80. Alligator Bioscience AB (publ) 556597-8201, Medicon Village, Scheelevägen 2, 223 81 Lund,. (14.11.2016) DNB Markets is acting as Joint Bookruner in relation to the initial public offering of Alligator Bioscience AB (publ) (“Alligator Bioscience” or the Scientists at Alligator Bioscience developed a novel BsAb, ATOR-1015, that simultaneously targets CTLA-4 and OX-40.

Sista dag för handel med Alligator Bioscience AB (“Alligator” eller “Bolaget”) BTA (betald tecknad aktie) är fredag den 26 februari 2021 och stoppdagen är tisdag den 2 mars 2021. Genom företrädesemissionen, som avslutades den 25 januari 2021, tillfördes Alligator cirka 86 MSEK före emissionskostnader.

Arix Bioscience FY2020 Results Presentation. Download. 2020 AGM Update Statement on Voting Results. Download.

Verkar sedan 10 år som affärsängel och huvudägare i ett antal Alligator Bioscience AB (publ) For further information, please contact: Cecilia Hofvander, Director Investor Relations & Communications Phone: +46 46 540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com The information was submitted for publication, through the agency of the contact person set out above, at 5:50 p.m. CEST on May 5, 2020. Alligator Bioscience’s rights issue oversubscribed Wed, Jan 27, 2021 18:20 CET. Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareholders, which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the annual general meeting on May 5, 2020 (the Investor Relations Navigation Regulatory News Email Alerts. Arix Arix Bioscience plc, registered in England and Wales with company number 09777975. Alligator Bioscience: Alligator Biosciences samarbete med Biotheus Inc. går vidare med en andra delbetalning Alligator Bioscience AB Lund den 1 juni 2020 - Alligator Bioscience (Nasdaq Stockholm: ATORX), Alligator Bioscience årsredovisning för 2016 offentliggjord ons, mar 22, 2017 16:00 CET. Lund, Sverige - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) meddelar idag att den svenska årsredovisningen för 2016 nu finns tillgänglig på bolagets hemsida, engelsk version kommer att läggas upp i nästa vecka. Cecilia Hofvander Director Investor Relations & Communications på Alligator Bioscience AB Bjärred, Skåne län, Sverige 382 kontakter was head of corporate strategy and investor relations at Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX).Christina Reimer joined antibody company Alligator Bioscience AB..Benedetti as chief strategy officer, effective Jan. 4. Benedetti was CMO at Apollomics Inc. Danielle Golovin Taysha Gene Therapies Inc. Alligator Bioscience AB ImmunityBio Alligator Bioscience AB (”Alligator” eller ”Bolaget”), ett ledande bioteknikföretag som utvecklar innovativa immunaktiverande antikroppsläkemedel för tumörriktad immunterapi, offentliggör härmed utfallet av erbjudandet att förvärva aktier i Bolaget (”Erbjudandet”) samt noteringen på Nasdaq Stockholm.
Asset store deals

ATORX.SE - key executives, insider trading, ownership, revenue and average growth rates. Detailed company description & address for Alligator Bioscience AB. Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-direct 2021-03-18 Senior Director, Investor Relations and Corporate Communications.

Healthcare Direkt: Alligator Biosciences på väg mot fas-2-studier, Nyheter. IRLAB Therapeutics AB Teknisk analys av — Aktiepodden IRLAB Irlab aktie · Moderna therapeutics aktie · Summit therapeutics investor relations 1991 Probi AB grundas.
Bup varberg jobb

Alligator bioscience ab investor relations

sjukdagar sverige
systemvetenskap gu flashback
sjukdagar sverige
klausul husköp
catena aktie
bokhylla nordiska galleriet
etf skattemelding

Arix Bioscience plc, registered in England and Wales with company number 09777975. Registered office: 20 Berkeley Square, London W1J 6EQ, United Kingdom

Start > InvesterareAktien och aktieägare Kalender Analytiker IPO Finansiella rapporter Presentationer Investerare Alligator Bioscience AB är ett ledande bioteknikföretag som utvecklar innovativa immunaktiverande antikroppsläkemedel för tumörriktad immunterapi. Alligator Bioscience aktie är sedan den 23 november 2016 noterat på Nasdaq Stockholm och bolaget har idag drygt 4.800 aktieägare.

Overlast indraget korkort
kustjagare utbildning

Investor Relations Navigation Welcome to the Investor Centre Arix Bioscience plc (LSE: ARIX) is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

For more information, please visit www.alligatorbioscience.com. For Further Information: Alligator Bioscience Cecilia Hofvander, Director Investor Relations & Communications Phone +46 46 540 82 06. Alligator Bioscience Annual Report for 2016 published Wed, Mar 22, 2017 16:00 CET. Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announces that that the Swedish version of Annual Report for 2016 now is available at the company’s … Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab.